Argenx announces ADAPT OCULUS study met primary endpoint

Argenx (ARGX) announced topline results from the Phase 3 ADAPT OCULUS study evaluating Vyvgart in adults with ocular myasthenia gravis. ADAPT OCULUS met its primary endpoint, showing that patients living with oMG and treated with Vyvgart demonstrated statistically significant improvement from baseline in Myasthenia Impairment Index Patient Reported Outcome ocular scores at Week 4 compared to placebo. In the overall population, mean change from baseline in patients treated with Vyvgart was a 4.04 point improvement in MGII PRO versus a mean change of 1.99 MGII PRO score in patients treated with placebo. Patients treated with Vyvgart experienced a marked reduction of key ocular symptoms: diplopia and ptosis. Vyvgart was well tolerated and had a favorable safety profile in patients with oMG, consistent with prior studies. No new safety concerns were identified. Data from the ADAPT OCULUS study will be presented at an upcoming medical meeting.